Abstract
High radiation doses may be delivered to the prostate with EBRT or BT. Both low (LDR)- and high dose-rate (HDR) BT have been used as means of dose escalation in randomized controlled trials (RCTs) comparing EBRT to BT boost. These trials have repeatedly demonstrated an improvement in biochemical disease-free survival (bDFS). Yet, the toxicity Results were inconsistent and the trials were underpowered to detect overall survival (OS) differences. Furthermore, to date, there is no randomized data comparing LDR to HDR boost. We aimed to conduct a systematic review and meta-analysis of RCTs to assess survival and toxicity outcomes in men with localized prostate cancer treated with EBRT versus BT boost.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
